Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model
Author
dc.contributor.author
Díaz Dinamarca, Diego A.
Author
dc.contributor.author
Hernández, Carlos
Author
dc.contributor.author
Escobar, Daniel F.
Author
dc.contributor.author
Soto, Daniel A.
Author
dc.contributor.author
Muñoz, Guillermo A.
Author
dc.contributor.author
Badilla, Jesús F.
Author
dc.contributor.author
Manzo, Ricardo A.
Author
dc.contributor.author
Carrión, Flavio
Author
dc.contributor.author
Kalergis, Alexis M.
Author
dc.contributor.author
Admission date
dc.date.accessioned
2020-10-15T23:21:42Z
Available date
dc.date.available
2020-10-15T23:21:42Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Vaccines 2020, 8, 146
es_ES
Identifier
dc.identifier.other
10.3390/vaccines8020146
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177173
Abstract
dc.description.abstract
Group BStreptococcus(GBS) is the primary etiological agent of sepsis and meningitis in newborns and is associated with premature birth and stillbirth. The development of a licensed vaccine is one of the pending challenges for the World Health Organization. Previously, we showed that oral immunization with surface immune protein (SIP) decreases vaginal colonization of GBS and generates functional opsonizing antibodies, which was determined by opsonophagocytic assays (OPA) in vitro. We also showed that the protein has an adjuvant vaccine profile. Therefore, an oral vaccine based on SIP may be an attractive alternative to employ in the development of new vaccines against GBS.Lactococcus lactisis a highlighted oral vaccine probiotic inducer of the mucosal immune response. This bacterium could serve as an antigen-delivering vehicle for the development of an edible vaccine and has been used in clinical trials. In this study, we showed that an oral vaccine with a recombinantL. lactisstrain secreting SIP from GBS (rL. lactis-SIP) can induce protective humoral and cellular immunity in an experimental model of GBS vaginal colonization in C57BL/6 mice. Mice immunized withrL. lactis-SIP were protected against clinical symptoms and bacterial colonization after GBS vaginal colonization. OurrL. lactis-SIP vaccine also induces an increase of immunoglobulin G (IgG) and immunoglobulin A (IgA) specifically against SIP. The adoptive transfer of serum from vaccinated mice to naive mice generated protection against GBS vaginal colonization. Moreover, therL.lactis-SIP strain induces the activation of SIP-specific T cells, which could decrease GBS vaginal colonization and generate protective antibodies when transferred to other mice. Our experimental observations strongly support the notion thatrL. lactis-SIP induces protective humoral and cellular immunity and could be considered as a novel alternative in the development of vaccines for GBS.
es_ES
Patrocinador
dc.description.sponsorship
FONDEF
D10i1202
Millennium Institute on Immunology and Immunotherapy
P09/016-F
Instituto de Salud Publica de Chile (Institute of Public Health in Santiago, Chile)
CONICYT-PFCHA/Magister Nacional
22190189
Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model